← Leaderboards
Ketankumar D. Patel
St. John'S University
$1,405,548
Attributed
$1,405,548
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $656K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,405,548 · 3
By mechanism
R16$585,548 · 1
R15$492,000 · 1
SC2$328,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorTumor XenograftSolubilityToxic EffectTumor VolumeResistance DevelopmentMalignant NeoplasmsProteinsDrug Delivery SystemsTargeted TreatmentSolid NeoplasmApoptosisFormulationResistanceDrug KineticsCell LineIn VivoLaboratoriesAnti-CancerClinically RelevantProtacBody WeightRecruitUbiquitin-Protein Ligase
Grant awards (7)
Combination of tumor targeted therapy with stroma modulating agent for PDAC$164,000
R16 · FY2025 · GM · contact PI
Combination of tumor targeted therapy with stroma modulating agent for PDAC$164,000
R16 · FY2024 · GM · contact PI
Combination of tumor targeted therapy with stroma modulating agent for PDAC$93,548
R16 · FY2024 · GM · contact PI
Synergistic combination of Proteolysis Targeting Chimera with a translational formulation for the treatment of intractable lung carcinoma$492,000
R15 · FY2023 · CA · contact PI
Combination of tumor targeted therapy with stroma modulating agent for PDAC$164,000
R16 · FY2023 · GM · contact PI
Oral nanoformulation for the treatment of BRAF inhibitor resistant melanoma$164,000
SC2 · FY2021 · GM · contact PI
Oral nanoformulation for the treatment of BRAF inhibitor resistant melanoma$164,000
SC2 · FY2020 · GM · contact PI